ECDC Forward Look Risk Assessment: Seasonal influenza 2010–2011 in Europe
The 2010/11 seasonal influenza epidemics in Europe are dominated so far by the A(H1N1)2009 viruses which emerged in the 2009 pandemic, although these are now considered seasonal viruses. This is an interim risk assessment and will be up-dated at intervals as more data and analyses emerge.
ECDC Forward look risk assessment (Update 28 October 2010): Likely scenarios and uncertainties in the 2010/2011 influenza season in Europe and beyond
Likely scenarios and uncertainties in the 2010/2011 influenza season in Europe and beyond.
Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation
This report summarises the results from two epidemiological studies conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium undertaken in eight European Union (EU)/European Economic Area (EEA) countries in order to investigate a possible association between an unexpected increase in narcolepsy cases following the use of influenza A(H1N1)pdm09 vaccines. Narcolepsy is an underdiagnosed disease of widely unknown etiology.
Technical report In Brief: Narcolepsy in association with pandemic influenza vaccination
This report summarises the results from two epidemiological studies to investigate a possible association between an unexpected increase in narcolepsy cases following the use of the influenza A(H1N1)pdm09 vaccines. The studies were conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium under the auspices of ECDC and undertaken in Denmark, Finland, France, Italy, the Netherlands, Norway, Sweden and the United Kingdom. This Technical Report In Brief accompanies the full Report ‘Narcolepsy in association with pandemic influenza vaccination- A multi-country European epidemiological investigation’.
Weekly influenza surveillance overview, Nov 15, 2013 - week 45
During week 45/2013: All 27 reporting countries experienced low intensity influenza activity.
Influenza virus characterisation, July 2014
During the 2013–14 season, A(H1N1)pdm09, A(H3N2), B/Victoria- and B/Yamagata-lineage influenza viruses have continued to co-circulate in EU/EEA Member States.
Guide to public health measures to reduce the impact of influenza pandemics in Europe – ‘The ECDC Menu’
This document presents a menu of possible public measures to be taken during influenza pandemics, giving public health and scientific information on what is known or can be said about their likely effectiveness, costs (direct and indirect), acceptability, public expectations and other more practical considerations. The ‘ECDC Menu’ aims to help EU Member States and institutions, individually or collectively, decide which measures they will apply.
Protocols for case-control studies to measure influenza vaccine effectiveness in the EU and EEA Member States
This publication presents the core European protocol for a series of proposed influenza vaccine effectiveness studies. The protocol includes a proposed plan for pooled analysis and has recently been adapted to measure vaccine effectiveness for the pandemic vaccine in 2009-10. Together with its twin publication ‘Protocols for cohort database studies to measure influenza vaccine effectiveness in the EU and EEA Member States’, this publication covers all methodological issues in the design and implementation of vaccine effectiveness studies, both for seasonal and the new A(H1N1)v influenza.
Training workshop on vaccine safety for Member States, building on the experience obtained in the ECDC vaccine safety project VAESCOArchived
ECDC organised a workshop aimed at the Member States not participating in the ECDC Vaccine safety network.
Understanding the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines
This meeting was designed to offer a place to exchange the latest information on into the development of narcolepsy following vaccination with one of the 2009 adjuvanted influenza A(H1N1) vaccines.